6 Results for "

vasorelaxing

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "vasorelaxing" in MCE Product Catalog:

Cat. No.: HY-120979
CAS No.: 791122-48-0
Target:  

Angiotensin Receptor

Research Areas:  

Cardiovascular Disease

NO-Losartan A (compound 2a) displays vasorelaxing effects, due to the release of NO, and antagonized the vasocontractile effects of Angiotensin II (HY-13948), with potency values similar to that of Losartan (HY-17512) .
loading...
    loading...
Cat. No.: HY-P1556
CAS No.: 141676-35-9
Target:  

PKG

Research Areas:  

Cardiovascular Disease

Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .
loading...
    loading...
Cat. No.: HY-N3547
CAS No.: 4030-51-7
Synonyms: Cassythine
Cassyfiline (Cassythine) is an aporphine alkaloid. Cassyfiline has potent vasorelaxing effects on precontracted rat aortic preparations with an IC50 of 0.09 μM .
loading...
    loading...
Cat. No.: HY-119306
CAS No.: 181238-67-5
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

MCC-134, a blocker of mitochondrial and opener of surface ATP-sensitive K+ (KATP) channels, abrogates cardioprotective effects of chronic hypoxia. MCC-134 is a vasorelaxing agent .
loading...
    loading...
Cat. No.: HY-122212
CAS No.: 780825-97-0
Target:  

Adrenergic Receptor

Research Areas:  

Cardiovascular Disease

PF-9404C is a potent beta-adrenergic blocker and a vasorelaxing agent. PF-9404C can be used as NO-donor. PF-9404C shows antihypertensive and cardioprotective action .
loading...
    loading...
Cat. No.: HY-P1556A
Target:  

PKG

Research Areas:  

Metabolic Disease

Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .
loading...
    loading...